SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported results for the fourth quarter and full year ended December 31, 2005. For the fourth quarter 2005, revenues from the sale of ZADAXIN®, SciClone’s lead product, increased by 22% to $7,314,000, compared with revenues of $5,985,000 reported for the fourth quarter 2004. For the full year ended December 31, 2005, product revenues increased by 22% to $27,842,000, compared with product revenues of $22,765,000 for 2004. The increase in product revenues for the fourth quarter and year ended December 31, 2005 is primarily attributable to an increase in the quantity of ZADAXIN sold to the China market, which accounts for approximately 91% of overall ZADAXIN sales.
